production of a vaccine
for the new H1N1 strain. Sinovac has contacted various Chinese government
authorities and global health organizations in order to closely monitor the
disease and evaluate strategies to control and prevent its transmission. In
May, high ranking government officials visited Sinovac to gain a better
understanding of our capacity to produce the H1N1 vaccine. In 2008, following
the receipt of a Chinese government grant, Sinovac expanded its annual
manufacturing capacity for its pandemic influenza vaccine, Panflu(TM), to 20-
30 million doses; these facilities can also be leveraged in the development of
a new H1N1 flu vaccine. Sinovac expects to receive the H1N1 virus strain by
the end of May, which would enable the Company to commence manufacturing the
vaccine as needed. In addition to Chinese authorities, Sinovac has also
received inquiries from other countries and regions. Sinovac has filed its
application for a pandemic influenza (H5N1) vaccine in Hong Kong and submitted
an influenza vaccine dossier to its distribution partner in India.
In May, Sinovac filed a registration dossier for a split pandemic
influenza vaccine with the China SFDA to ensure children and juveniles are
protected during an influenza pandemic. This is a complementary product to the
Company's whole viron pandemic influenza vaccine, Panflu, protects adults from
this virus and was approved in April 2008. SFDA has initiated the review and
approval process for the split pandemic influenza vaccine and expects to
receive the approval shortly. Once Sinovac receives approval, the Company's
vaccines that protect larger age groups from pandemic influenza.
In addition, Sinovac is expanding beyond the human vaccine market by
entering into the animal vaccine market as there is a sizable market
opportunity for animal vaccines. Tangshan Yian, Sinovac's wholly owned
subsidiary, is focusing on the animal vaccine business to help drive grow
'/>"/>
SOURCE Sinovac Biotech Ltd. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine news :1.
Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China2.
Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims3.
Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death4.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites5.
Haemacure Reports Third Quarter 2007 Results6.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion7.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best8.
MDS Reports Third Quarter 2007 Results9.
Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 200610.
AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System11.
NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results